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OBJECTIVES: Acute kidney injury (AKI) is a common complication in hospitalized patients with cirrhosis which
contributes to morbidity and mortality. Improved prediction of AKI in this population is needed for
prevention and early intervention.We developed amodel to identify hospitalized patients at risk for AKI.
METHODS: Admission data from a prospective cohort of hospitalized patients with cirrhosis without AKI on
admission (n 5 397) was used for derivation. AKI development in the first week of admission was
captured. Independent predictors of AKI on multivariate logistic regression were used to develop the
prediction model. External validation was performed on a separate multicenter cohort (n 5 308).
RESULTS: In the derivation cohort, the mean age was 57 years, the Model for End-Stage Liver Disease score was
17, and 59 patients (15%) developed AKI after amedian of 4 days. Admission creatinine (OR: 2.38 per
1 mg/dL increase [95% CI: 1.47–3.85]), international normalized ratio (OR: 1.92 per 1 unit increase
[95% CI: 1.92–3.10]), and white blood cell count (OR: 1.09 per 13 109/L increase [95% CI:
1.04–1.15]) were independently associated with AKI. These variables were used to develop
a prediction model (area underneath the receiver operator curve: 0.77 [95% CI: 0.70–0.83]). In the
validation cohort (mean age of 53 years, Model for End-Stage Liver Disease score of 16, and AKI
development of 13%), the area underneath the receiver operator curve for themodel was 0.70 (95%CI:
0.61–0.78).
DISCUSSION: A model consisting of admission creatinine, international normalized ratio, and white blood cell count
can identify patients with cirrhosis at risk for in-hospital AKI development. On further validation, our
model can be used to apply novel interventions to reduce the incidence of AKI among patients with
cirrhosis who are hospitalized.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A92
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INTRODUCTION
Acute kidney injury (AKI) is an important complication of
decompensated cirrhosis that drives poor outcomes (1,2). AKI
is present in 20% (3) of patients with cirrhosis admitted to the
hospital, and it develops in up to 19% after admission (4). Its
development is independently associated with high short-term
mortality and leads to significant morbidity after discharge
from the hospital (5,6).
Given the significant burden and prognostic implications of
AKI, accurate risk stratification in this population is crucial for
efforts to prevent, recognize, and treat AKI to improve outcomes.
Although a rise in serum creatinine (Scr) is the cornerstone of
AKI diagnosis (7), early recognition is hindered as acute changes
in Scr are often delayed due to the time required for creatinine to
accumulate and equilibrate. In addition, factors such as ascites,
malnutrition, and sarcopenia which are common in hospitalized
patients with cirrhosis contribute to spurious creatinine-based
estimates of renal function and can prevent the early recognition
of patients at risk (8). Novel renal biomarkers such as cystatin C
and neutrophil gelatinase-associated lipocalin may allow for
improved risk assessment (9), but these research tools are ex-
pensive and remain far fromclinical use (2). Thus, there is amajor
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unmet need for an accurate tool to predict AKI in hospitalized
patients with cirrhosis.
An AKI prediction model using readily available objective
clinical parameters could be valuable to identify patients at high
risk for AKI. Accurate identification of high-risk patients will
allow for early intervention and appropriate allocation of hospital
resources to improve patient care and outcomes. Furthermore,
development of a prediction model could aid clinical trial design
for AKI prevention by identifying patients at highest risk.
Thus, this study develops a simple, objective model to predict
AKI development in hospitalized patients with cirrhosis. To
identify those at risk promptly, we examined data collectedwithin
the first 24 h of hospitalization from a large prospective cohort of
hospitalized patients. Further validation of the predictive model
was performed on an independent external cohort.
PATIENTS AND METHODS
Study design
We created a model to predict in-hospital AKI using a prospective
cohort of patients with cirrhosis who were nonelectively admitted
to Indiana University Hospital. The Indiana University Hospital is
the largest referral and academic tertiary care hospital in the state of
Indiana. External validation of the prediction model was per-
formed using a multicenter retrospective cohort of hospitalized
patients with cirrhosis. The diagnosis of cirrhosis was made based
on clinical parameters involving laboratory tests, endoscopic or
radiologic evidence of cirrhosis, evidence of decompensation (he-
patic encephalopathy, ascites, variceal bleeding, jaundice), and liver
biopsy if available. Thosewhomet inclusion criteria (see section on
“Inclusion Criteria”) were included for the analysis. The derivation
and validation of the prediction model was designed according to
the TRIPOD guidelines (10). The protocol was approved by the
Institutional Review Board at our center.
Inclusion criteria. The study inclusion criteria were the
following:
1. Availability of a baseline Scr as defined by the International
Club of Ascites (7).
2. Availability of the following laboratory studies within 24 h of
admission: complete blood count, basic metabolic profile,
hepatic panel, and international normalized ratio (INR).
Patients excluded from the analysis were those who did not
meet the inclusion criteria as well as the following: those who had
previously undergone liver or kidney transplant, had AKI on
admission, and had acute or chronic requirement of hemodialysis
at the time of admission, and those with missing laboratory
measurements within 24 h of admission.
Definition of AKI. AKI was defined by the Kidney Disease Im-
provingGlobal Outcomes guideline (11), which has been endorsed
by the International Club of Ascites (7) for patients with cirrhosis.
Because urine outputdocumentation canbeunreliable (7), only the
rise in Scr$ 0.3 mg/dL or$ 1.53 baseline was used to define the
in-hospital development of AKI. The primary outcome was AKI
development up to 7 days after admission. AKI beyond 7 days was
not included in the primary outcome because of the practical dif-
ficulty in predicting AKI later in the hospitalization based on the
admission data. Stages of AKI were defined by Kidney Disease
Improving Global Outcomes (11) staging system which has also
been endorsed by the International Club of Ascites: stage 1, in-
crease in Scr . 0.3 mg/dL or increase in Scr $ 1.5–23 baseline;
stage 2, increase in Scr . 23–33 increase from baseline; stage 3,
increase in Scr .33 from baseline or Scr . 4.0 mg/dL with an
acute increase$ 0.3 mg/dL or initiation of hemodialysis.
Derivation cohort
Patients who were prospectively enrolled from June 2014 to
October 2018 andmet the inclusion criteria were included for the
analysis. The etiology of cirrhosis, history of complications re-
lated to cirrhosis, demographics, reason for hospitalization, daily
vital signs, and laboratory data (complete blood count, metabolic
panel, and hepatic panel) from the day of admission to day 14 of
hospitalizationwere collected. In addition, the status of infections
(on admission and during the hospitalization), phenotype of AKI
(prerenal azotemia, acute tubular necrosis, hepatorenal syn-
drome type 1, and other), precipitants of AKI (large-volume
paracentesis, excessive use of diuretics, spontaneous bacterial
peritonitis (SBP), non-SBP infections, portal hypertensive-
related bleeding, intravenous contrast, and other), and 30-day
mortality details were collected. The etiology of cirrhosis was
categorized into viral hepatitis C (HCV), HCV and alcohol, al-
cohol, nonalcoholic steatohepatitis, and other. Cirrhosis severity
was calculated using the Model for End-Stage Liver Disease
(MELD) (12) and Child-Turcotte-Pugh (13) scores. Acute on
chronic liver failure (ACLF) and its severity (grades 1–3) were
defined by the CLIF Consortium Organ Failure Score (14).
Validation cohort
Patientswhowere admitted nonelectively to 4 safety-net hospitals
(Baylor College of Medicine Medical Center, Boston University
Medical Center, Eskenazi Medical Center, and John Stroger
Hospital of Cook County Health) in 2012 were screened for in-
clusion criteria. Details of this cohort have been previously de-
scribed (15). Data collected were analogous to the derivation
cohort, with the exception of phenotype of AKI, ACLF details,
precipitants of AKI, and mortality.
Context of use
The current study was designed to create a prediction model for
AKI development in hospitalized patients with cirrhosis. The
potential decisions to be made based on the model are the in-
tensity of kidney functionmonitoring, potential AKI prophylaxis
with volume administration, inclusion criteria for preventive
clinical trial design, and avoidance of certain nephrotoxins.
Statistical analysis
Patients were stratified based on the development of AKI or not,
and their characteristics on admission were compared. Contin-
uous variables were presented as mean 6 SD and median with
interquartile range (IQR) where appropriate. Categorical varia-
bles were presented as percentages. Differences across the groups
with respect to categorical variables were analyzed using x2 test
andFisher Exact test, whereas continuous variableswere analyzed
using the nonparametric Kruskal-Wallis test and student t test. A
2-sided nominal P value of less than or equal to 0.05 was con-
sidered significant.
Derivation of the AKI prediction model. Variables of clinical
significance were considered for themultivariate analysis. These
were baseline Scr, admission Scr, white blood cell count (WBC),
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mean arterial pressure, INR, admission sodium, admission total
bilirubin, admission albumin, presence of infection on admis-
sion, ascites, age, and gender (Table 1). The variables were or-
dered based on univariate significance by fitting a logistic
regression model and added into the multivariate model using
a forward selection procedure. Highly correlated variables were
compared and included only once.Model selectionwas based on
minimizing Akaike information criterion and maximizing area
underneath the receiver operator curve (AUROC) or concor-
dance c-statistic, with priority given to the lowest Akaike in-
formation criterion. The final model was then applied to the
validation cohort, and AUROC analysis was performed for the
prediction of AKI. The diagnostic performance of the model in
both derivation and validation cohorts was evaluated using
sensitivity, specificity, positive predictive value, negative pre-
dictive value, and diagnostic accuracy at 90% sensitivity, 90%
specificity, and the maximum Youden index. The final model
was then compared with the MELD-Na and the CLIF Consor-
tium Acute Decompensation (CLIF-AD) (16) scores via
DeLongs method. All analyses were performed in SAS ver-
sion 9.4.
RESULTS
Derivation cohort
A total of 627 patients were enrolled during the study period.
After excluding those who did not meet the inclusion criteria
(229 patients in total: 191 had AKI on admission and 38 had
missing admission labs), a total of 397 patients were included
for the analysis (59 with AKI development [14%] and 338
without AKI development).
Patient characteristics. The mean age of the entire cohort was
57.3 6 10.8 years. Fifty-seven percent were men, with a mean
MELD score of 17.2 6 6.1. Nonalcoholic steatohepatitis (33%),
alcohol (27%), andHCV (15%) were themost common etiologies
of cirrhosis. Those who developed AKI had a significantly higher
baseline Scr, admission Scr, admission total bilirubin, admission
INR, admission blood urea nitrogen, admission WBC, and ad-
mission MELD score compared with the non-AKI group
(Table 1). The presence of infection was found to be significantly
higher in the AKI group compared with the non-AKI group (21%
and 11%, respectively; P 5 0.023). The AKI group had more
admissions for ascites/anasarca and fewer admissions for portal
hypertensive-related bleeding (Table 1).
One hundred seventy-five patients hadACLFon admission, of
which 31 patients developed AKI. There were no differences
between the 2 groups for the presence of ACLF on admission
(54% AKI development vs 42% no AKI development; P5 0.120)
(Table 1). However, there were differences across ACLF grades
between the 2 groups (P 5 0.001), with a higher percentage of
patients having ACLF grade 3 who developed AKI (34%) vs
patients who did not develop AKI (18%; P 5 0.003).
AKI development details and hospitalization outcomes. The
median (IQR) time to AKI development was 4 (3–5) hospital
days. Ninety-five percent of patients had stage 1AKI at the time of
diagnosis, followed by 5% for stage 2. The most frequent pre-
cipitant for AKI identified was non-SBP infections (32% overall),
followed by excessive use of diuretics (19%). SBP was found to be
the cause of AKI in 7% of patients.
In those who had stage 1 AKI at the time of diagnoses, 68%
stayed at stage 1 and the rest progressed to stages 2 and 3 (16%
and 10%, respectively). The most frequent phenotype of AKI
was prerenal at 52%, followed by acute tubular necrosis at 19%
and type 1 hepatorenal syndrome at 3%. Ten percent of
patients with AKI required hemodialysis during the hospital-
ization. Compared with the non-AKI group, patients
who developed AKI had significantly higher in-hospital mor-
tality (16% vs 2%; P, 0.001) and 30-daymortality (28% vs 6%;
P , 0.001).
Validation cohort
A total of 733 patients were screened for inclusion criteria. Four
hundred twenty-five patients were excluded (170 patients with
AKI on admission and 255 patients with missing admission
data), leaving 308 patients for the analysis (41 with AKI de-
velopment [13%] and 267without AKI).Most of themweremen
(73%), and the meanMELD score was 15.96 5.9. Similar to the
derivation cohort, patients who developed AKI had higher
baseline Scr, admission Scr, admission total bilirubin, admission
INR, admission blood urea nitrogen, admission WBC, and ad-
mission MELD score compared with the non-AKI group (see
Table 1, Supplementary Digital Content, http://links.lww.com/
CTG/A92). In addition, the presence of infection was found to
be significantly higher in the AKI development group (42%)
compared with the non-AKI group (15%) (P # 0.0001). Com-
parisons between the derivation and validation cohorts can be
found in Supplementary Table 2 (Supplementary Digital Con-
tent, http://links.lww.com/CTG/A92).
Themedian (IQR) time to AKI development was 2 (1–3) days,
and 73%, 20%, and 8% had stage 1, 2, and 3 at the time of AKI
diagnosis. Thirty-one percent of patients diagnosed at stage 1
progressed to higher stages ofAKI, and 63%of patientswith stage 2
AKI progressed to stage 3. Seven percent of patients required
hemodialysis.
AKI prediction model
The admission variables that were found to be significant for AKI
development on univariate analysis in the derivation cohort are
listed in Table 2. Onmultivariate analysis, admission Scr (OR: 2.38
per 1 mg/dL increase [95% CI: 1.47–3.85]), INR (OR: 1.92 per 1
unit increase [95% CI: 1.92–3.10]), and WBC (OR: 1.09 per 1 3
109/L increase [95%CI: 1.04–1.15]) were independently associated
with AKI. Using these variables, a logistic regression model was
created for prediction:
AKI Prediction Score :
2 4:591 0:0893WBC1 0:873 Scr1 0:653 INR:
Predicted probability of AKI
¼ expð2 4:591 0:0893WBC1 0:873 Scr1 0:653 INRÞ
11 expð2 4:591 0:0893WBC1 0:873 Scr1 0:653 INRÞ:
The AUROC for prediction was found to be 0.77 (95%CI: 0.70,
0.83; P, 0.0001) (Figure 1), and the Akaike information criterion
was 298. The AKI prediction model was found to have a numeri-
cally higher AUROC than MELD-Na score (0.71 [95% CI: 0.63,
0.79]) andCLIF-AD score (0.73 [95%CI: 0.66, 0.80]), although the
differenceswerenot statistically significant (P50.08vsMELD-NA
and P5 0.13 vs CLIF-AD).
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The diagnostic performance of the AKI prediction model is
shown inTable 3.With the sensitivity and specificityfixed at 90%, the
negative predictive value was high at 96% and 88%, respectively. The
diagnostic accuracy was highest with a cutoff.21.21 (specificity at
90%) at 82%. When the logistic regression AKI prediction model
from the derivation cohort was applied to the validation cohort, the
Table 1. Comparisons of admission characteristics stratified by AKI status
Characteristic Development of AKI (n 5 59) Non-AKI (n5 338) P value
Mean age (6SD) 56.6 (10.8) 57.6 (11) 0.305
Sex, n (% male) 35 (59) 186 (55) 0.540
Race, n (% white) 58 (98) 316 (94) 0.344
Etiology of cirrhosis, n (%)
Alcohol 20 (34) 90 (27)
HCV 7 (12) 53 (15) 0.687
HCV and alcohol 3 (5) 30 (9)
NASH 21 (36) 111 (33)
Other 8 (13) 54 (16)
Baseline creatinine, mg/dL (6SD) 1.3 (0.7) 1.0 (0.5) ,0.001
CTP stage, n (%)
A 1 (2) 20 (6)
B 13 (22) 118 (35) 0.033
C 45 (76) 197 (59)
MELD (6SD) 21.2 (7.9) 16.5 (5.5) ,0.001
Presence of ACLF, n (%) 31 (53) 144 (43) 0.120
ACLF grade, n (%)
1 4 (7) 5 (1)
2 7 (12) 79 (23)
3 20 (34) 60 (18) 0.001
Ascites, n (%)
None 5 (9) 82 (24)
Controlled 9 (15) 99 (29) ,0.001
Uncontrolled 45 (76) 157 (46)
Sodium, mmol/L (6SD) 130.9 (7.5) 133.5 (5.5) 0.002
Creatinine, mg/dL (6SD) 1.3 (0.6) 1.0 (0.5) ,0.001
BUN, mg/dL (6SD) 28.8 (18.2) 19.7 (12.4) ,0.001
Albumin, g/dL (6SD) 2.7 (0.6) 2.9 (0.6) 0.022
INR (6SD) 1.9 (0.7) 1.6 (0.5) ,0.001
Total bilirubin, mg/dL (6SD) 6.1 (5.9) 4 (4.5) 0.002
WBC,3 109 (6SD) 9.4 (7.2) 6.6 (4.3) ,0.001
Mean arterial pressure (6SD) 82.7 (14.1) 85.4 (14.6) 0.186
Presence of infection, n (%) 12 (21.4) 32 (10.6) 0.023
Reason for admission, n (%)
Overt hepatic encephalopathy 14 (25) 88 (26)
PHTN-related bleed 3 (5) 59 (18) 0.042
Ascites/anasarca 16 (27) 52 (15)
Other 14 (23) 69 (20)
Liver unrelated 12 (20) 70 (21)
ACLF, acute on chronic liver failure; AKI, acute kidney injury; BUN, blood urea nitrogen; CTP, Child-Turcotte-Pugh; HCV, hepatitis C virus; INR, international normalized
ratio; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PHTN, portal hypertension; WBC, white blood cell count.
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AUROCwas 0.70 (95%CI: 0.61, 0.78;P, 0.0001) (Figure 2). Similar
to thederivation cohort, a score of.21.21had adiagnostic accuracy
at 82%, with a specificity of 90%.
DISCUSSION
In this study, we have derived and externally validated a pre-
dictivemodel for the development of AKI in hospitalized patients
with cirrhosis. Our model is based on 3 objective measures that
are widely available in clinical practice (Scr, INR, and WBC) and
can therefore be applied in a variety of hospitalized settings. The
AUROC for prediction of AKI in the derivation cohort was 0.77,
and the AUROC in an independent validation cohort was 0.70.
The pathophysiology of AKI in patients with cirrhosis is com-
plex and often related to renal vasoconstriction secondary to the
effective hypovolemia that occurs in advanced cirrhosis and portal
hypertension (17). Furthermore, it is increasingly recognized that
Table 2. Independent predictors for acute kidney injury prediction
Admission predictor
Univariate Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Creatinine 2.32 (1.48–3.65) ,0.001 2.38 (1.47–3.85) ,0.001
WBC 1.10 (1.04–1.15) ,0.001 1.09 (1.04–1.15) 0.001
INR 2.07 (1.31–3.27) 0.002 1.92 (1.19–3.10) 0.008
Baseline creatinine 2.16 (1.39–3.35) 0.001
Sodium 0.93 (0.89–0.98) 0.002
Total bilirubin 1.07 (1.02–1.13) 0.003
Albumin 0.55 (0.33–0.92) 0.022
Presence of infection 2.31 (1.11–4.82) 0.026
Ascites
Controlled vs none 1.06 (0.35–3.19) 0.2308
Uncontrolled vs none 3.20 (1.29–7.95) 0.0008
Mean arterial pressure 0.99 (0.97–1.01) 0.186
Age 0.99 (0.96–1.01) 0.305
Male 1.19 (0.68–2.09) 0.541
CI, confidence interval; INR, international normalized ratio; WBC, white blood cell count.
Figure 1. Area underneath the receiver operating curve for the prediction of acute kidney injury in the derivation cohort.
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AKI is associated with systemic and intrarenal inflammation
(18–21). Patients with advanced cirrhosis have higher levels of
circulating endotoxins, possibly due to bacterial translocation
across the intestinal wall (22,23), thus promoting the production of
manyproinflammatory cytokines, substances that cause peripheral
and splanchnic vasodilation (24,25), as well as intrarenal endo-
thelial dysfunction and cell damage (20,26). Each of these patho-
physiologic elements is indirectly captured by the variables in our
predictive model. For example, a high WBC, a surrogate of sys-
temic inflammation, is a known independent predictor ofmortality
in patients with advanced cirrhosis and is a driver for the de-
velopment of ACLF (19,27). An elevated WBC has also been as-
sociated with renal dysfunction in patients with SBP (28,29) and
alcoholic hepatitis (30). The other 2 components of the risk score
were INR and Scr. INR is a well-knownmarker of progressive liver
failure and therefore worsening portal hypertension (12,13) which
has been linked to renal impairment (17,31,32). Furthermore, de-
spite its limitations, we found Scr to have the highest OR of 2.38 for
1 mg/dL increase. Our findings are in line with other studies
(33–35), where higher Scr is independently associated with AKI
development and poor renal outcomes.
There are several limitations to our study. First, although urine
output is not considered a part of the diagnostic criteria for AKI
by the International Club of Ascites (7), we were not able to
compare our risk score with early urine output. Urine output
should be evaluated in future studies because it has been shown to
be sensitive for incident AKI (36). Similarly, we were unable to
compare our model with novel kidney biomarkers (e.g., cystatin
C, neutrophil gelatinase-associated lipocalin) for risk assessment.
Thus, future studies are also needed to assess these kidney
Table 3. Diagnostic performance of the AKI prediction model
Selected cutoffs Raw score Sensitivity (%) Specificity (%) PPV (%) NPV (%) Diagnostic accuracy (%)
Derivation cohort
90% sensitivity* 22.38 90 39 20 96 46
Maximum Youden index 21.82 63 74 29 92 72
90% specificity* 21.21 31 90 37 88 82
Validation cohort
90% sensitivity* 22.38 81 44 18 94 49
Maximum Youden Index 21.82 46 78 25 91 74
90% specificity* 21.21 29 90 32 89 82
NPV, negative predictive value; PPV, positive predictive value.
*Fixed at sensitivity and specificity closest to 90% but $90%.
Figure 2. Area underneath the receiver operating curve for the prediction of acute kidney injury in the validation cohort.
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biomarkers to substantiate their roles as clinical tools and to as-
sess if the addition of biomarkers enhances prediction. Last, be-
cause only 5% of patients had AKI stage 2 or higher at the time of
diagnosis, we were unable to determine if our model is applicable
to predict higher stages of AKI. In contrast to these weaknesses,
the study benefits from the use of a multicenter external valida-
tion cohort, with numerous significant differences comparedwith
the derivation cohort. These differences highlight the potential
generalizability of the model, which may be applied in diverse
settings to predict AKI.
The ability to risk stratify patients early during their hospitali-
zation has several important implications for clinicalmanagement.
For example, a patient without AKI on admission with an INR of
2.5, WBC of 15, and Scr 2.0 would have an AKI risk score of 0.11,
corresponding to a 7-day risk ofAKI of 53%with.80%diagnostic
accuracy. By contrast, a patient with an INR of 1.7,WBC of 10, and
Scr of 0.8 would have an AKI risk score of21.89, corresponding to
a much lower risk of 13%. Hence, knowledge of individual patient
risk for AKI may allow the treating physician to personalize the
intensity of laboratory monitoring and to be mindful in the use of
intravenous diuretics or iodinated contrast. Furthermore, risk
stratification could provide a standardized approach for future
clinical trials focusing on AKI prevention. Therefore, though not
yet proven, themodel has a clear potential to influence therapeutic
or prognostic decisions in the future. An example of this would be
early administration of albumin or early hepatorenal syndrome-
directed therapy (albumin, terlipressin, etc.) in a patient at high risk
to develop hepatorenal syndrome. Our model of AKI prediction
calculator is available at http://gihep.com/calculators/hepatology/
aki-in-hospitalized-patients-with-cirrhosis/.
In conclusion, in this large prospective study of hospitalized
patients with cirrhosis, the development of in-hospital AKI is
common and confers a poor prognosis. Our model for AKI pre-
diction is based on 3 widely available laboratory parameters; it
captures the pathophysiologic elements of AKI, and itmay identify
patients at high risk for AKI. The use of this model may allow for
closer monitoring and early treatment to prevent AKI in those at
risk. Ultimately, future studies are required to demonstrate
whether this risk score can be used to improve clinical outcomes.
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Study Highlights
WHAT IS KNOWN
3 In-hospital AKI is a common complication of cirrhosis which
leads to significant morbidity and mortality.
3 There are no existing tools to predict in-hospital AKI in this
population. Creation of a prediction model may help guide
treatment and improve outcomes.
WHAT IS NEW HERE
3 Admission laboratory values (white blood cell count,
creatinine, and international normalized ratio) were used to
derive the AKI predictionmodel. Themodel had an AUROCof
0.77 (95% CI: 0.70–0.83; P , 0.001) for AKI prediction.
3 When validated in a separate multicenter cohort, the AUROC
for AKI prediction was 0.70 (95% CI: 0.61–0.78; P, 0.001).
3 Our AKI prediction model may allow for prevention and timely
treatment of AKI to improve patient outcomes.
TRANSLATIONAL IMPACT
3 Our AKI prediction model may allow for prevention and timely
treatment of AKI to improve patient outcomes.
3 Furthermore, risk stratification via our AKI model could
provide a standardized approach for future clinical trials
focusing on AKI prevention.
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